Definium Therapeutics Inc Ordinary Shares DFTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Definium Therapeutics Announces New Employee Inducement Grants
-
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
-
Definium Therapeutics Announces New Employee Inducement Grants
-
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
-
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
-
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
-
Definium Therapeutics Announces New Employee Inducement Grants
-
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 134.37M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 106
- Website
- https://www.definiumtx.com
Valuation
|
Metric
|
DFTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DFTX
|
|---|---|
Quick Ratio | 6.89 |
Current Ratio | 6.95 |
Interest Coverage | −72.02 |
Quick Ratio
DFTX
Profitability
|
Metric
|
DFTX
|
|---|---|
Return on Assets (Normalized) | −39.03% |
Return on Equity (Normalized) | −51.94% |
Return on Invested Capital (Normalized) | −48.77% |
Return on Assets
DFTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?!vwm@h | LOCK|%hTKH | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#cxGBhR | LOCK|bD#% | $76B | |||
| Moderna Inc
MRNA
| LOCK|dKf@v?? | LOCK|%r | $75B | |||
| argenx SE ADR
ARGX
| LOCK|rY>$ks | LOCK|Zk# | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|djTt<> | LOCK|!r | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ct@B>zn | LOCK|@^>< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nQ@>J@<$ | LOCK|hx^VL | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|P#bBvZp | LOCK|w& | $24B | |||
| Incyte Corp
INCY
| LOCK|DHtJ$@ | LOCK|^CX | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ghT^m> | LOCK|D!q | $15B |
United States